为了观察抗肿瘤新药诺维本联合化疗治疗晚期非小细胞肺癌 (NSCL C)的疗效及毒性反应 ,将晚期 NSCL C46例初治患者随机分为 2组 ,2 6例为 NP方案 :诺维本 (NVB) +顺铂 (DDP) ,2 0例为 NE方案 :诺维本 (NVB) +表阿霉素 (EPI)。 46例患者 CR 0例 ,PR 2 2例 ,总有效率 47.8%。白细胞减少发生率 :NP组 :78.8% ,NE组 :70 .0 % ;静脉炎发生率 :NP组 :48.0 % ,NE组 :42 .5 %。结果提示 :以诺维本为主的联合化疗治疗晚期非小细胞肺癌有效率高 ,毒性可以耐受 ,NP、 NE两组比较 ,有效率及毒性均无显著性差异 ,惟 NE组采用表阿霉素 ,治疗费用提高。 In order to observe the curative effect and toxicity of antitumor drug Novubibac in combination with chemotherapy for advanced non-small cell lung cancer (NSCL C), C46 patients with advanced NSCL were randomly divided into two groups, 26 patients were treated with NP regimen: (NVB) + cisplatin (DDP), 20 cases of NE program: NVB + epirubicin (EPI). 46 cases of CR 0 cases, PR 2 2 cases, the total efficiency of 47.8%. The incidence of leukopenia: NP group: 78.8%, NE group: 70.0%; Phlebitis incidence: NP group: 48.0%, NE group: 42.5%. The results suggest that the combination of chemotherapy with novibenzamide is effective and tolerable in the treatment of advanced non-small cell lung cancer. There is no significant difference in the efficacy and toxicity between the NP and NE groups Mycophenolate, treatment costs increase.